Monday, August 28, 2017

Complete remission of brain metastasis of difficult-to-treat tumor

Here is a link to an article describing a new treatment for a brain metastasis of the difficult-to-treat tumor diffuse large-B-cell lymphoma (DLBCL), which had become resistant to chemotherapy -- the first report of a response to CAR T-cells in a central nervous system lymphoma.

An excerpt.

In a letter to the New England Journal of Medicine, a Massachusetts General Hospital (MGH) research team reports a remarkable treatment response in a patient participating in a clinical trial of a novel immune-system-based cancer therapy. Treatment with an investigational CAR T-cell therapy induced complete remission of a brain metastasis of the difficult-to-treat tumor diffuse large-B-cell lymphoma (DLBCL), which had become resistant to chemotherapy -- the first report of a response to CAR T-cells in a central nervous system lymphoma.

In addition, when a subcutaneous tumor began to recur two months after CAR T-cell therapy and a surgical biopsy was performed, the CAR T-cells spontaneously re-expanded and the tumor again went into remission, and phenomenon that had not previously been reported. While the patient eventually relapsed and died more than a year after CAR T-cell therapy, the brain tumor never recurred.

No comments: